LUNG Quote, Financials, Valuation and Earnings

Electromed has a net margin of -69.38% compared to Pulmonx's net margin of 10.05%. Pulmonx's return on equity of -51.95% beat Electromed's return on equity of 15.62%.

Pulmonx has a consensus price target of --, signalling upside risk potential of 90.36%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 15.18%. Given that Pulmonx has higher upside potential than Electromed, analysts believe Pulmonx is more attractive than Electromed.

Pulmonx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

Pulmonx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Pulmonx quarterly revenues are $20.4M, which are larger than Electromed quarterly revenues of $14.7M. Pulmonx's net income of -$14.1M is lower than Electromed's net income of $1.5M. Notably, Pulmonx's price-to-earnings ratio is -- while Electromed's PE ratio is 39.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx is 3.06x versus 4.48x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -69.38% compared to Pulmonx's net margin of -16.69%. Pulmonx's return on equity of -51.95% beat IRIDEX's return on equity of -157.91%.

Pulmonx has a consensus price target of --, signalling upside risk potential of 90.36%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 26.58%. Given that Pulmonx has higher upside potential than IRIDEX, analysts believe Pulmonx is more attractive than IRIDEX.

Pulmonx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IRIDEX has a beta of 0.812, suggesting its less volatile than the S&P 500 by 18.837%.

Pulmonx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Pulmonx quarterly revenues are $20.4M, which are larger than IRIDEX quarterly revenues of $11.6M. Pulmonx's net income of -$14.1M is lower than IRIDEX's net income of -$1.9M. Notably, Pulmonx's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx is 3.06x versus 0.53x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -69.38% compared to Pulmonx's net margin of -10.5%. Pulmonx's return on equity of -51.95% beat Myomo's return on equity of -84.04%.

Pulmonx has a consensus price target of --, signalling upside risk potential of 90.36%. On the other hand Myomo has an analysts' consensus of $7.04 which suggests that it could grow by 27.14%. Given that Pulmonx has higher upside potential than Myomo, analysts believe Pulmonx is more attractive than Myomo.

Pulmonx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Myomo has a beta of 1.709, suggesting its more volatile than the S&P 500 by 70.858%.

Pulmonx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Pulmonx quarterly revenues are $20.4M, which are larger than Myomo quarterly revenues of $9.2M. Pulmonx's net income of -$14.1M is lower than Myomo's net income of -$966.4K. Notably, Pulmonx's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx is 3.06x versus 8.81x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -69.38% compared to Pulmonx's net margin of -67.31%. Pulmonx's return on equity of -51.95% beat Stereotaxis's return on equity of -108.68%.

Pulmonx has a consensus price target of --, signalling upside risk potential of 90.36%. On the other hand Stereotaxis has an analysts' consensus of -- which suggests that it could grow by 91.49%. Given that Stereotaxis has higher upside potential than Pulmonx, analysts believe Stereotaxis is more attractive than Pulmonx.

Pulmonx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.570, suggesting its more volatile than the S&P 500 by 57.046%.

Pulmonx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Pulmonx quarterly revenues are $20.4M, which are larger than Stereotaxis quarterly revenues of $9.2M. Pulmonx's net income of -$14.1M is lower than Stereotaxis's net income of -$6.2M. Notably, Pulmonx's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx is 3.06x versus 7.87x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.